Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships

Published:September 2011

No. of Pages: 188

Price: $2265

Report Summary

An examination of trends and advances in the three major drug delivery sectors

Unique sales forecasts to 2020 for key products
Critical analyses of 58 specialist developers driving the drug delivery market onwards
Increasingly, pharmaceutical companies are turning to drug delivery developers to overcome a range of challenges in getting novel new medicines and formulations effectively and safely delivered. Indeed, it can be argued that identifying an efficient delivery method is as important as the therapy itself. This new report assesses three key emerging sectors in the drug delivery field that will play a crucial role in tackling a range of delivery issues associated with these new classes of drugs in key therapeutic areas such as cancer, CNS, cardiology, respiratory and ophthalmology. 

This report provides a detailed insight into the current and future market and...

• Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed
• Identifies key application areas
• Appraises currently available products which utilise advanced delivery platforms
• Examines new product developments from major specialist drug delivery companies, critically analysing their prospects
• Allows ready comparison on different technologies within a company’s portfolio.

Use this report to

• Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies
• Identify and review licensing and collaborative partners
• Understand the merits and applications of the main approaches being researched.
• A complete analysis packed with market facts, sector forecasts to 2020 and detailed company evaluations...' Lipid-based delivery Questions answered
• Many new chemical entities are poorly water soluble which may affect a drug’s bioavailability and efficacy. Advanced drug delivery systems using biocompatible lipid-based technologies can be used to improve solubility, increase bioavailability (enhance absorption) and efficacy, helping to reduce the level of drug dosage and decrease the incidence and severity of adverse effects.

To date more than a dozen products have been approved that utilise some of the first generation lipid-based technologies, pioneered by Elan Pharmaceuticals, Enzon, Gilead Pharmaceuticals, ALZA (acquired by Johnson & Johnson), Skye Pharma, and The Liposome Company (acquired by Elan Pharmaceuticals). These products encompass anaesthetics, antiinfectives and oncology agents and together generate over US$1.85 billion in sales annually.

• Research activity is intensive and the top 20 drug delivery specialists are currently investigating more than 75 products in preclinical and clinical development; over half of these products (c.46 products) are likely to reach the market by 2020 to generate global sales in excess of US$2.6 billion by 2020. What are the competing technologies to Lipocine’s Lip’ral?
• Which products in research exploit Aradigm’s proprietary inhalable drug technology?
• Who is bank-rolling NanoBio’s R&D programme?
• Tekmira has 6 potential product launches coming up - what are the sales forecasts to 2020?
• What research is being undertaken with lipid-based platforms for the delivery of targeted products?

 Polymer-based delivery Questions answered.

The pharmaceutical industry has been utilising advanced polymer-based delivery technologies to improve the pharmacokinetics and targeted delivery of small and large molecule drugs. 

To date more than two dozen products have been approved that utilise PEGylation technologies developed by some of the industry pioneers, such as ALZA, Endo Pharmaceuticals and Nektar Therapeutics. In addition, several specialists have developed controlled-release polymer matrix to prolong the release of active pharmaceutical ingredients in situ with technologies developed by Debiopharm Group and Durect.

• By 2020 we forecast that nearly 60 novel polymer-based products could reach the market to generate global sales in excess of US$5 billion through improved pharmacokinetics of approved and new compounds, as well as the emergence of novel biologics, nucleic acidbased medicines and small molecule agents. Which companies are working in the colonic drug delivery area?
• Which company acquired Biocompatibles International to gain access to the polymer-based bead technology sector?
• How important will the urological treatment Urocidin be to Endo Pharmaceutical’s financial health?
• What opportunities are there in polymer-based transdermal delivery?

Biovectors/Gene Therapy/Vaccines Questions answered

During the last twenty years there have been significant advances in the manufacture, development and delivery of gene therapies, RNA therapies and vaccines. No single biovector stands out for each field and many different development strategies have been adopted to optimise delivery.
 

Gene-related medicines have achieved limited success to date - no gene therapies have been approved and only a few antisense drugs have carved out a therapeutic niche in ocular diseases (Vitravene; CMV, Macugen; wet AMD). However, R&D investment for gene related products continues to grow at a fast rate and this highlights the challenges and opportunities which face developers, delivery technologists and regulators in this field.

• In contrast, interest in the vaccine market has rocketed fuelled by biodefence programmes and the outbreak of avian influenza as well as advances in vaccine production technologies which has lowered the barrier to entry for the smaller players. Whilst infectious diseases, particularly influenza and HIV, remain a major area of interest, therapeutic vaccines are emerging to gain a share of the marketplace. Which product sector is set to exceed sales of US$2 billion by 2020?
• Which company commenced Phase II trials in January 2011 for a DNA vaccine to treat leukaemia?
• Which company has AtuRNAi products in Phase II development for Macular Oedema and Agerelated Macular Degeneration?
• 10 companies are active in the field of oncology. Who are they and what is their pipeline?

 In addition to the areas covered in this report the following sectors have also been analysed
Advanced Oral & Parenteral Drug Delivery Technologies: Published January 2011, covering
Oral | Parenteral

Drug Delivery Technologies to 2018: Published June 2009, covering
Controlled-Release Delivery | Nano-Enabled Delivery | Nucleic Acid Delivery | Targeted Delivery

Drug Delivery Insight

Whether your interest is commercial, financial, scientific or technological, no other business publication comes close to Drug Delivery Insight for providing such a comprehensive overview of the latest developments in every area of drug delivery. Available in print or daily updated online.

Table Of Contents

About the Author.1
Dr Cheryl L Barton.1
Executive Summary.2
Introduction3
Types of lipid-based delivery platforms4
Applications in drug discovery and product development7
Oral & buccal.8
Parenteral10
Pulmonary/Intranasal.10
Transdermal/Topical.10
Delivery profiles.11
Nano-enabled delivery.11
Controlled delivery11
Targeted delivery.11
Applications in different therapeutic areas 13
Oncology.13
Infectious diseases.16
CNS & Pain.16
Respiratory16
Cardiology.16
Ocular.16
Other16
Top 20 Company Profiles.17
AlphaRx Corporation17
Aphios Corporation.19
Aradigm Corporation21
Axentis Pharma AG24
Azaya Therapeutics.26
Bio-Path Holdings27
Camurus AB30
Celsion Corporation.33
Clavis Pharma ASA.35
Cornerstone Pharmaceuticals.37
Insys Therapeutics.38
Latitude Pharmaceuticals.39
Lipocine.41
Marina Biotech.42
Merrimack Pharmaceuticals45
NanoBio Corporation47
Novagali Pharma SA49
Talon Therapeutics51
Taiwan Liposome Company.52
Tekmira Pharmaceuticals Corporation55
Up & Coming Lipid-Bas ed Drug Delivery Specialists.58
Conclusions60
Bibliography & Endnotes.62
Executive Summary 64
Introduction. 65
Types of polymer-bas ed delivery platforms.67
Applications in drug discovery and product development. 69
Oral & buccal 69
Parenteral. 69
Transdermal. 71
Delivery Trends 72
Nano-enabled delivery 72
Controlled delivery. 72
Targeted delivery 72
Therapeutic trends. 73
Oncology 76
Neurology & Pain 76
Cardiology 76
Gastroenterology. 76
Metabolic. 76
Other. 77
Top 20 Company Profiles 78
Access Pharmaceuticals. 78
Alkermes.80
BioDelivery Sciences International 83
BTG International84
Calando Pharmaceuticals88
Debiopharm Group 89
Durect Corporation 91
Expression Genetics. 93
Endo Pharmaceuticals 95
Enzon Pharmaceuticals 98
Labopharm100
Mersana Therapeutics. 102
Mountain View Pharmaceuticals.104
Nanocarrier105
Nektar Therapeutics.108
OctoPlus N.V110
Samyang Pharmaceuticals.112
Supratek Pharma.115
SurModics116
Teikoku Pharma USA.119
Up & Coming Polymer-Bas ed Drug Delivery Specialists121
Outlook123
Bibliography & Endnotes.125
Executive Summary.128
Introduction129
Types of biovectors.130
Viral vectors. 130
Adeno-associated virus vectors.130
Adenovirus vectors.130
Alphavirus vectors.130
Lentivirus vectors130
Poxvirus vectors131
Other viral vectors.131
Non-viral vectors. 132
Bacteria132
Yeast.132
Advanced drug delivery systems.132
Lipid-based delivery.133
Polymeric-based delivery.133
Delivery devices.133
Applications in the development of gene therapies, RN Ai therapeutics and vaccines    134
Delivery trends.136
Gene Therapies. 136
RNA Therapeutics. 136
Vaccines 136
Therapeutic trends137
Gene Therapies. 138
RNA Therapeutics. 138
Vaccines 139
Top 20 Company Profiles 140
Gene Therapies.140
RNA Therapeutics.140
Vaccines140
Gene therapy delivery.141
Ark Therapeutics. 141
Ceregene 143
Expression Genetics.144
Neurologix. 145
Oxford BioMedica .147
RN A Therapeutic Delivery Specialists.149
Alnylam Pharmaceuticals 149
Calando Pharmaceuticals 151
CureVac GmbH 153
Marina Biotech 154
Santaris Pharma A/S. 157
Silence Therapeutics 159
Tekmira Pharmaceutical Corporation. 161
Va ccine delivery specialists 164
Crucell N.V164
GlobeImmune.166
Inovio Pharmaceuticals. 169
Ichor Medical Systems. 172
Juvaris BioTherapeutics. 173
Lipotek Pty. 176
Vical. 177
VIRxSys. 179
Up & Coming Gene Therapy, RN Ai Therapeutics and Va ccine Delivery Specialists182
Outlook. 185
Bibliography & Endnotes. 187